Summary
Psoriasis, an autoimmune disorder characterized by keratinocyte hyperproliferation, predominantly manifests as plaque-type psoriasis, with a majority of cases being mild to moderate. Current treatment approaches, such as topical therapy, often fall short due to limited skin permeability. Systemic drugs and biologics, while effective, pose risks associated with high doses. Addressing mild psoriasis presents the challenge of overcoming limited skin permeability and minimizing systemic drug toxicity. Microneedle Array patches (MAPs) offer a promising alternative. They breach the stratum corneum, facilitating intradermal drug delivery, resulting in higher localized drug concentrations compared to systemic or topical administration. Given the pivotal role of TNF-α in psoriasis, I bring expertise in various MAP fabrication techniques, nanomaterials for drug and mRNA delivery, and their applications. By collaborating with the host, we aim to develop an innovative nanomedicine-based strategy. This approach involves encapsulating TNF-α inhibitors in calcium phosphate nanoparticles using flame spray pyrolysis and loading them into MAPs. The research will encompass various parameters, including size, encapsulation efficiency, release kinetics, mechanical strength, morphology, safety, and in vitro efficacy assessment. Beyond the research project, I will engage in personal development courses, gain exposure to state-of-the-art laboratory facilities, and participate in conferences. Additionally, I will mentor Master's and Ph.D. students, honing my project management skills, and collaborate with industry experts and clinicians to explore the formulation's potential.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101153133 |
| Start date: | 01-03-2025 |
| End date: | 28-02-2027 |
| Total budget - Public funding: | - 222 727,00 Euro |
Cordis data
Original description
Psoriasis, an autoimmune disorder characterized by keratinocyte hyperproliferation, predominantly manifests as plaque-type psoriasis, with a majority of cases being mild to moderate. Current treatment approaches, such as topical therapy, often fall short due to limited skin permeability. Systemic drugs and biologics, while effective, pose risks associated with high doses. Addressing mild psoriasis presents the challenge of overcoming limited skin permeability and minimizing systemic drug toxicity. Microneedle Array patches (MAPs) offer a promising alternative. They breach the stratum corneum, facilitating intradermal drug delivery, resulting in higher localized drug concentrations compared to systemic or topical administration. Given the pivotal role of TNF-α in psoriasis, I bring expertise in various MAP fabrication techniques, nanomaterials for drug and mRNA delivery, and their applications. By collaborating with the host, we aim to develop an innovative nanomedicine-based strategy. This approach involves encapsulating TNF-α inhibitors in calcium phosphate nanoparticles using flame spray pyrolysis and loading them into MAPs. The research will encompass various parameters, including size, encapsulation efficiency, release kinetics, mechanical strength, morphology, safety, and in vitro efficacy assessment. Beyond the research project, I will engage in personal development courses, gain exposure to state-of-the-art laboratory facilities, and participate in conferences. Additionally, I will mentor Master's and Ph.D. students, honing my project management skills, and collaborate with industry experts and clinicians to explore the formulation's potential.Status
SIGNEDCall topic
HORIZON-MSCA-2023-PF-01-01Update Date
03-10-2024
Images
No images available.
Geographical location(s)
